Takeda research and development chief Andy Plump is set to retire in June 2027 after leading a strategic transformation since 2015. Plump's tenure included the $62 billion acquisition of Shire and a shift toward biotech partnerships, alongside setbacks like abandoning cell therapy. His departure follows Takeda's August 2026 approvals for narcolepsy and blood cancer treatments, which, with a pipeline psoriasis drug, are projected to generate over $8 billion in annual sales.
Andy Plump retirement announcement
- ▪Andy Plump will remain president of research and development at Takeda until a successor is found, and will stay on Takeda's board of directors through the shareholder meeting in June 2027
- ▪Takeda research and development chief Andy Plump will retire from the company in June 2027
Takeda R&D transformation strategy
- ▪Andy Plump joined Takeda in 2015 to lead a strategic and cultural transformation of the company's research and development organization
- ▪Under Andy Plump's leadership, Takeda built a rare disease business through a $62 billion acquisition of Shire in 2019
Partnership approach with biotechs
- ▪Under Andy Plump's leadership, Takeda expanded its drug pipeline by establishing a larger web of partnerships and looking to China for potential new blockbuster drugs
- ▪Andy Plump pushed Takeda to work more closely with young biotechnology companies, emulating the dealmaking approach of Celgene to rejuvenate Takeda's drug pipeline
Pipeline setbacks
- ▪Takeda experienced setbacks including the withdrawal of a lung cancer medication, a regulatory misfire for a dengue vaccine, and production challenges that halted manufacturing of a rare endocrine condition treatment
- ▪Takeda announced in 2025 that it would abandon its cell therapy work, which had previously been designated as a strategic priority for the company
- ▪Loss of exclusivity on older top-selling products prompted Takeda to undertake a restructuring and lay off thousands of workers
Recent drug approvals
- ▪In August 2026, Takeda won regulatory approval for a first-of-its-kind blood cancer therapy
- ▪In August 2026, Takeda won regulatory approval for an eagerly anticipated narcolepsy medicine
Future pipeline outlook
- ▪Takeda is developing an immune disease drug that has succeeded in testing for psoriasis and could potentially be used against other conditions
- ▪Jefferies analyst Stephen Barker estimates that Takeda's three new products could eventually generate more than $8 billion in annual sales
Story comments
Loading comments…